NCT00882076 2019-07-24
Clofarabine, Etoposide, and Mitoxantrone for Relapsed and Refractory Acute Leukemias
Milton S. Hershey Medical Center
Phase 1 Terminated
Clinical Trials
8 trialsNCT00780104 2019-07-12
UPCC 02407
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00003003 2018-03-19
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT02631252 2018-02-23
Phase I Study of Mitoxantrone and Etoposide Combined With Hydroxychloroquine, for Relapsed Acute Myelogenous Leukemia
University of Pittsburgh
Phase 1 Terminated
NCT00940524 2014-04-10
Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00028899 2014-02-20
Monoclonal Antibody Plus Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes
Children's Oncology Group
Phase 1 Completed
NCT00002912 2013-02-01
Combination Chemotherapy Plus PSC-833 in Treating Children With Refractory or Relapsed Acute Leukemia
National Cancer Institute (NCI)
Phase 1 Completed
NCT00107354 2010-09-20
Cellular Adoptive Immunotherapy in Treating Patients With Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes That Relapsed After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Phase 1 Completed